Small molecule degraders of disease-driving proteins offer a clinically proven modality with
enhanced therapeutic efficacy and the potential to tackle previously undrugged targets …

Targeted protein degradation and stabilization are promising therapeutic modalities due to
their potency and versatility. However, only few E3 ligases and deubiquitinases have been …

Targeted protein degradation is an emerging strategy for drug discovery that employs small
molecules to catalyze the ubiquitination of target proteins, ultimately causing their …

Proteolysis targeting chimeras are bifunctional small molecules capable of recruiting a target
protein of interest to an E3 ubiquitin ligase that facilitates target ubiquitination followed by …

Targeted protein degradation is a broad and expanding field aimed at the modulation of
protein homeostasis. A focus of this field has been directed toward molecules that hijack the …

Controlled perturbation of protein activity is essential to study protein function in cells and
living organisms. Small molecules that hijack the cellular protein ubiquitination machinery to …

Targeted protein degradation (TPD) using the ubiquitin proteasome system (UPS) is a
rapidly growing drug discovery modality to eliminate pathogenic proteins. Strategies for TPD …

Targeted protein degradation (TPD) relies on a comprehensive understanding of interfaces
between hijacked E3 ligases and their substrates. In vitro techniques often do not capture …

Ubiquitination is an essential process that curtails cellular levels of damaged and redundant
proteins. Chemical biologists have harnessed this natural system to induce the degradation …

The therapeutic modality of targeted protein degradation promises to overcome limitations of
traditional pharmacology. Small-molecule degraders recruit disease-causing proteins to E3 …